ABSTRACT: Guideline-based medical therapy is the foundation of treatment for individuals with coronary artery disease. However, revascularization with either percutaneous coronary intervention or coronary artery bypass grafting may be beneficial in patients with acute coronary syndromes, refractory symptoms, or in other specific scenarios (eg, left main disease and heart failure). While the goal of percutaneous coronary intervention and coronary artery bypass grafting is to achieve complete revascularization, anatomical and ischemic definitions of complete revascularization and their methodology for assessment remain highly variable. Such lack of consensus invariably contributes to the absence of standardized approaches for invasive treatment of coronary artery disease. Herein, we propose a novel, comprehensive, yet pragmatic algorithm with both anatomical and ischemic parameters that aims to provide a systematic method to assess complete revascularization after percutaneous coronary intervention or coronary artery bypass grafting in both clinical practice and clinical trials.

Key Words: coronary artery bypass ■ percutaneous coronary intervention ■ revascularization

While guideline-based medical therapy remains the foundation of treatment for patients with coronary artery disease, in some patients, such as those with acute coronary syndromes, symptoms refractory to medical therapy, and specific anatomical findings (ie, left main and multivessel disease and left ventricular dysfunction), coronary revascularization may deliver additional benefits.1,2 Complete revascularization (CR), in which all of a patient’s “significant” anatomic or ischemic lesions are treated, is the goal of revascularization for most patients with coronary artery disease. However, in many clinical scenarios, CR is not feasible because of factors such as comorbidities, coronary anatomy, or operator skill. In these circumstances, incomplete revascularization (ICR), in which “significant” untreated residual coronary artery disease persists, is present. Understanding the impact of CR and ICR from the literally hundreds of studies that have examined this relationship has been confounded by the use of widely varying definitions and methodologies for assessment between studies. We herein propose a comprehensive yet straightforward algorithm for assessing CR in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).

PREVIOUS DEFINITIONS USED FOR ANATOMIC AND ISCHEMIC ASSESSMENT OF THE COMPLETENESS OF REVASCULARIZATION

Multiple definitions have been proposed for CR and ICR to date. Each definition is based on anatomical parameters, ischemic parameters, or a combination of the 2.3 The degree of anatomic disease is typically...
described by the presence of lesions with stenosis severity greater than a certain percent diameter stenosis (DS) in vessels with reference vessel diameter (RVD) greater than a pre-established threshold. Most studies have defined anatomic CR as the successful treatment of all coronary lesions with a visually estimated DS of either ≥50% or ≥70% in vessels with RVD either ≥1.5 or ≥2.0 mm.4–7 When the criteria for anatomic CR are not met, there is anatomic ICR. The magnitude of anatomical ICR may be assessed by the residual SYNTAX score (rSS). In several studies, a gradient of outcomes has been observed from rSS=0 (CR) to rSS of 1 to 8 to rSS of ≥9, with rSS of ≥9 indicating the presence of the greatest residual coronary artery disease.8 Alternatively, the magnitude of anatomical ICR may also be assessed using a Jeopardy score.9

The severity of ischemic disease is based on the presence of nonrevascularized territories identified from preprocedural noninvasive stress testing, invasive pressure wire–based physiological assessment,11,12 or occasionally the same testing postrevascularization (fractional flow reserve [FFR] ≤0.80, Pd/Pa ≤0.91 or instantaneous-wave free ratio [iFR]/resting full-cycle ratio [RFR]/diastolic pressure ratio [DPR] ≤0.89).12,13 When the criteria for ischemic CR are not met, there is ischemic ICR. The magnitude of ischemic ICR has been assessed by the number of nonrevascularized arteries with baseline ischemia, often measured as jeopardizing a percentage of the myocardium, or residual pressure gradient (FFR/Pd/Pa/iFR/RFR/DPR).14–17

RATIONALE FOR A STANDARDIZED DEFINITION OF CR

There exists no class I level of evidence, societal guidelines, or expert consensus guiding the completeness of coronary artery revascularization. Only recently, in 2018 and 2019, have the European Society of Cardiology/European Association for Cardio-Thoracic Surgery guidelines commented on CR, emphasizing the significant evidence gap and its importance in the context of selecting the mode of revascularization, either PCI or CABG.1 No specific guidance as to when CR is preferred or in which patients ICR is reasonable is provided. Instead, the circumstances in which CR should be pursued rely largely on observational data, especially for patients with stable coronary artery disease,3 and remains the decision of individual operators guided by their past experience. The importance of CR (whether anatomic and/or ischemic) and whether choice of revascularization method should be dictated by the likely ability to achieve CR has not been addressed in prior American College of Cardiology/American Heart Association guidelines.

RECOMMENDATIONS FOR STANDARDIZED DEFINITIONS OF ANATOMIC AND ISCHEMIC CR

We propose a comprehensive algorithm based on patient anatomic and physiological parameters to (1) define anatomic and ischemia-producing coronary artery disease; (2) define anatomic and ischemic CR (and thus ICR); (3) define acceptable severity of baseline disease not requiring revascularization (based on current expert consensus); and (4) define anatomic and ischemic CR at the lesion, vessel, and patient level. In each case, recommendations are given for lesion measurements that may be applied in clinical practice (visually estimated) or quantitatively assessed in a core laboratory for use in clinical investigations.

Completeness of Anatomic Revascularization

Anatomically, coronary artery disease has most typically been considered to be "significant" when the DS is ≥50% by quantitative coronary angiography (QCA) or visual estimation (VE).18 In direct comparison studies, there is consistency between QCA and VE measurements in 50% to 60% stenoses, whereas VE tends to be larger than QCA in ≤50% DS and smaller than QCA >60% DS.19 Thus, we propose that when a coronary artery lesion has a QCA or VE DS of <50%, the lesion is considered non-flow-limiting, and does not require revascularization (Figure 1). Similarly, since RVD is an independent predictor of target vessel failure in the short term and long term,20 small coronary arteries supply a limited amount of myocardium,15 the smallest commercially available
DES is 2.0 mm, and RVD is overestimated by VE compared with QCA, we propose that when a coronary artery has a QCA RVD of <2 mm or VE RVD of <2.25 mm, the vessel is considered too small for likely benefit of anatomical revascularization. Thus, lesions with pre-PCI QCA or VE DS ≥50% that are ≥2.0 mm by QCA or ≥2.25 mm by VE are considered anatomically revascularized if the residual DS is <30% by QCA or VE after PCI or after bypass grafts are placed distal to the lesions (Figure 1). Anatomical ICR is primarily dependent upon the extent of residual coronary lesions with QCA or VE DS ≥50% as calculated by the rSS. Those with rSS=0 should be classified as having undergone anatomic CR, rSS 1 to 8 may be considered reasonable ICR, and rSS ≥9 should be considered anatomic ICR. These criteria are the same for patients with and without left main coronary artery (LMCA) disease.

Anatomic CR at the vessel level is present if all lesions deemed to be anatomically significant at the lesion level have been revascularized (Figure 1). Anatomic CR is present at the patient level if all lesions deemed to be anatomically significant at the vessel level have been revascularized within 90 days, accounting for CABG waiting times and planned staged PCI procedures (Figure 1).

Completeness of Ischemic Revascularization
Lesion-level ischemia is considered to be present based on a hierarchy of ischemia testing (Figure 2).

First level—invasive physiology (to be used if data are present): in patients with 1 or more coronary lesions in vessels with QCA RVD ≥2.0 mm and DS ≥30% or VE RVD ≥2.25 mm and DS ≥40% for which FFR or nonhyperemic pressure ratio data are available, lesions that have an FFR ≤0.80, Pd/Pa ≤0.91, or iFR/...
Figure 2. Non-LMCA lesion-level ischemia assessment using invasive physiology and stress imaging–based criteria. DPR indicates diastolic pressure ratio; DS, diameter stenosis; ETT, exercise treadmill test; FFR, fractional flow reserve; iFR, instantaneous-wave free ratio; LAD, left anterior descending; LCX, left circumflex; LMCA, left main coronary artery; OM, obtuse marginal; QCA, quantitative coronary angiography; RCA, right coronary artery; RFR, resting full-cycle ratio; RVD, reference vessel diameter; and VE, visual estimation.
Angiography-based assessment of flow (quantitative flow ratio, virtual FFR), for both pre- and post-PCI physiology assessment may be used as an alternative to invasive intracoronary physiologic assessment, given their high diagnostic accuracy.

Second level—localizing noninvasive stress test (to be used if level 1 data are absent or incomplete): in patients with 1 or more lesions in vessels with coronary QCA RVD ≥2.0 mm or VE RVD ≥2.25 mm. If no invasive ischemic assessment is available, a noninvasive stress test (including stress myocardial perfusion with positron emission tomography, single-photon emission computed tomography, magnetic resonance imaging, or stress echocardiography) demonstrates vascular territory-specific inducible ischemia and lesions with a QCA or VE DS ≥50% subtending the territory of ischemia, the lesion should be designated as ischemic at baseline (Figure 2). Those lesions not meeting criteria should be designated as nonischemic. Ischemic CR is achieved if all lesions with a localizing noninvasive stress test undergo PCI with residual QCA or VE DS <30% or bypass grafts are placed distal to the lesions (Figure 2).

Third level—nonlocalizing noninvasive stress test (to be used if level 1 and 2 data are absent or incomplete): in patients with 1 or more lesions in vessels with coronary QCA RVD ≥2.0 mm or VE RVD ≥2.25 mm. If neither localizing invasive and noninvasive imaging data are available, but a treadmill exercise tolerance test has been performed and suggests a high burden of ischemia (at least 2 leads showing new exercise-induced ST-segment depression of at least 1.5 mm or a single lead of at least 2 mm, or exercise-induced ST-segment elevation of at least 1.5 mm in a noninfarct territory, as compared with the baseline tracing, occurring at an early stage [≤7 metabolic equivalents] or at heart rate <75% of age-predicted maximum), we recommend that lesions with a QCA DS ≥60% or VE DS ≥70% be designated as ischemic at baseline, reflecting the overestimation of QCA DS by VE at these thresholds. Since exercise tolerance tests are not accurate for disease localization, and are recognized to have inferior sensitivity to imaging-based modalities, the DS threshold is increased from 50% for localizing noninvasive stress tests to 60% by QCA and 70% by VE (Figure 2). Those lesions not meeting criteria are designated as nonischemic. Ischemic CR in patients with a positive nonlocalizing noninvasive stress test is achieved if all lesions with QCA DS ≥60% or VE DS ≥70% undergo PCI with residual QCA or VE DS <30% or bypass grafts are placed distal to the lesions (Figure 2).

Fourth level—no assessment of physiology or stress testing (to be used if levels 1, 2, and 3 data are absent or incomplete): in patients with coronary QCA RVD ≥2.0 mm or VE RVD ≥2.25 mm. If no invasive or noninvasive ischemic assessment is available, lesions that have a QCA ≥70% DS or VE ≥80% DS should be designated as ischemic at baseline. These thresholds are based on this degree of anatomic obstruction being associated with myocardial ischemia in ≈80% of patients with specificity >95%. Those lesions not meeting these criteria should be designated as nonischemic. Ischemic CR is achieved if all such lesions undergo PCI with residual QCA or VE <30% DS or a bypass graft is placed distal to each lesion (Figure 2).

Lesion-level ischemia and ischemic revascularization of the LMCA follows a modified algorithm (Figure 3). First, in patients with coronary lesions in vessels with QCA or VE DS ≥30% for which FFR or nonhyperemic pressure ratio data are available, isolated LMCA or LMCA equivalent lesions that have an FFR ≤0.80, Pd/Pa ≤0.91, or iFR/RFR/DPR ≤0.89 are designated as ischemic. For LMCA lesions with concomitant non-LMCA ischemic lesions in a single distal vessel, physiological assessment of the LMCA with the pressure wire in the disease-free daughter vessel that results in an FFR ≤0.80, Pd/Pa ≤0.91, or iFR/RFR/DPR ≤0.89 defines the LMCA lesion as ischemic. For LMCA lesions with downstream epicardial stenosis in both branches, the most severe distal non-LMCA lesions should be treated, followed by repeat LMCA assessment. Repeat assessment of the LMCA lesion that has an FFR ≤0.80, Pd/Pa ≤0.91, or iFR/RFR/DPR ≤0.89 then defines the LMCA lesion as ischemic. As a widely accepted surrogate measure, intravascular ultrasound imaging demonstrating a minimal lumen area of <6 mm² in the LMCA also defines the LMCA lesion as ischemic. Given the large amount of myocardium subtended by the LMCA, QCA or VE ≥30% DS in the presence of a co-localizing stress test, with ischemia in the anterior and posterolateral territories, or high-risk ECG findings on stress test (including exercise-induced hypotension), is designated as ischemic. Finally, lesions that have a QCA or VE ≥50% DS, with no other qualifying assessment, should be designated as ischemic by angiography. Those not meeting these criteria should be designated as nonischemic at baseline. Ischemic CR is achieved if the LMCA has a post-PCI residual QCA or VE <30% DS or bypass grafts are placed distal to the lesion. Bypass grafts may be placed to either the left anterior descending coronary
artery or left circumflex artery for isolated disease at the LM ostium or midshaft, or to both the left anterior descending coronary artery and left circumflex artery in the case of distal LM bifurcation involvement.

Ischemic CR at the vessel level is present if all lesions deemed to be ischemic at the lesion level have been revascularized (Figure 4). Ischemic CR is present at the patient level if all lesions deemed to be ischemic at the lesion level have been revascularized (Figure 4).

**Figure 3.** Left main level ischemia using invasive physiology and stress imaging–based criteria.

DPR indicates diastolic pressure ratio; DS, diameter stenosis; ETT, exercise treadmill test; FFR, fractional flow reserve; iFR, instantaneous-wave free ratio; IVUS, intravascular ultrasound; LMCA, left main coronary artery; MLA, minimal lumen area; QCA, quantitative coronary angiography; RFR, resting full-cycle ratio; and VE, visual estimation.
### Lesion Level Ischemia Assessment

#### Criteria for Ischemic Lesion

<table>
<thead>
<tr>
<th>Ischemia localized to lesion</th>
<th>Stress Test/Non-angiographic Criteria</th>
<th>Lesion Angiographic Criteria1</th>
<th>Left Main Lesion</th>
<th>LMCA Angiographic Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Positive invasive lesion physiological assessment</td>
<td>QCA DS ≥ 30% &amp; QCA RVD ≥ 2.00mm or VE DS ≥ 40% &amp; VE RVD ≥ 2.25mm</td>
<td>Positive invasive lesion physiological assessment FFR ≤ 0.80 Pa/Pd ≤ 0.91 IFR/FRF/DPR ≤ 0.89</td>
<td>QCA or VE DS ≥ 30%</td>
</tr>
<tr>
<td>Ischemia localized to territory</td>
<td>Significant vascular-territory specific inducible ischemia on stress imaging (NUC/ECHO/CMR)</td>
<td>Lesion in vascular territory with QCA DS ≥ 70% and QCA RVD ≥ 0.60 mm or VE DS ≥ 70% &amp; VE RVD ≥ 2.25mm</td>
<td>Ischemia in both anterior and posterolateral territories on imaging-based stress test</td>
<td>QCA or VE DS ≥ 30%</td>
</tr>
<tr>
<td>Non-localized ischemia</td>
<td>Severe ischemia by ETT</td>
<td>QCA DS ≥ 60% and QCA RVD ≥ 0.60 mm or VE DS ≥ 60% &amp; VE RVD ≥ 2.25mm</td>
<td>Severe ischemia by ETT with no qualifying non-LMCA ischemic lesion</td>
<td>QCA or VE DS ≥ 30%</td>
</tr>
<tr>
<td>Angiographic ischemia determination</td>
<td>No significant vascular territory specific inducible ischemia or no high risk ECG finding or no available stress test data</td>
<td>QCA DS ≥ 70% &amp; QCA RVD ≥ 0.60 mm or VE DS ≥ 80% &amp; VE RVD ≥ 2.25mm</td>
<td>No significant vascular territory specific inducible ischemia or no high risk ECG findings or no available stress test data or</td>
<td>QCA or VE DS ≥ 50%</td>
</tr>
</tbody>
</table>

1. Lesion not considered ischemic if patent graft supplying antegrade or retrograde vasculatization to territory.
2. Lesion in native vessel or in graft to vascular territory

### Ischemic Revascularization

#### 1. Lesion Level

- **Lesion is ischemic by invasive, non-invasive imaging, ETT or angiographic criteria?**
  - **Yes** → **Lesion non-ischemic at baseline**
  - **No** → **Lesion treated with residual QCA or VE DS ≤ 30% and no new side branch lesion1 or with bypass grafts distal to the lesion.**
    - **Lesion ischemia not revascularized**
    - **Yes** → **Lesion ischemia revascularized**

1. For lesion bypassed by a diseased graft either native vessel lesion or graft lesion can be treated.
2. New side branch lesion with QCA DS ≥ 70% and QCA RVD ≥ 2.00 mm or VE DS ≥ 70% and VE RVD ≥ 2.25 mm.

#### 2. Vessel Level (RCA, LAD, LCX, LM)

- **Ischemic lesion(s) present in vessel baseline?**
  - **Yes** → **Vessel lesion CR at baseline**
    - **All ischemic lesions in vessel successfully revascularized using lesion level criteria?**
      - **Yes** → **Vessel Ischemic CR**
      - **No** → **Vessel Ischemic ICR**
  - **No** → **Patient Ischemic CR at baseline**

#### 3. Patient Level

- **Ischemic lesion(s) present at baseline?**
  - **Yes** → **Patient Ischemic CR**
  - **No** → **Patient Ischemic CR**

All ischemic lesion(s) in RCA, LAD, LCX and left main successfully revascularized using lesion level criteria within 90 days?

---

**Figure 4.** Ischemic lesion, vessel, and patient-level revascularization assessment for LM, and non-LMCA.

DPR indicates diastolic pressure ratio; DS, diameter stenosis; ETT, exercise treadmill test; FFR, fractional flow reserve; IFR, instantaneous-wave free ratio; IVUS, intravascular ultrasound; LAD, left anterior descending; LCX, left circumflex; LMCA, left main coronary artery; MLA, minimal lumen area; QCA, quantitative coronary angiography; RCA, right coronary artery; RFR, resting full-cycle ratio; RVD, reference vessel diameter; and VE, visual estimation.
ischemic at the vessel level have been revascularized within 90 days, accounting for CABG waiting times and planned staged PCI procedures (Figure 4).

UNANSWERED QUESTIONS AND FUTURE DIRECTIONS

The algorithmic approach to CR aims to provide a comprehensive, data-driven, pragmatic and clinically relevant algorithm to guide optimal revascularization strategies in both clinical practice and clinical trials. As with any standardized system, we acknowledge its limitations. First, our lesion assessments are based on both QCA and VE. While VE is known to overestimate RVD and DS compared with QCA, the specific relationships between RVD and DS severity thresholds vary depending on the degree of stenosis.19,37 While QCA eliminates the substantial variability between operators when assessing vessel dimensions and stenosis severity,36 it is seldom used clinically, and thus VE is necessary for widespread adoption of the current approach. Second, the diagnostic accuracy of noninvasive imaging stress tests for disease in a specific coronary artery (ie, localization of ischemia) may be different for different arteries, and lower than accuracy of identification of obstructive coronary artery disease in general.39,40 Moreover, although more extensive involvement across the 12-lead ECG, particularly at submaximal exercise, may provide a measure of the severity of ischemia, it remains suboptimal for disease localization. Third, the specific thresholds for the diagnosis of anatomic and ischemic CR incorporated in the algorithm are based on expert consensus opinions derived from prior studies relating anatomic stenosis severity and physiology findings to outcomes (3). In this regard, the presence of unmeasured confounders prior studies likely influenced outcomes between patients achieving CR versus ICR. Fourth, the disparity between angiographic DS, by both QCA and VE, and the presence of ischemia assessed by invasive physiologic assessment are well established.5 We acknowledge the major limitations that exist with using angiographic DS cut-off values for determination of ischemia. While we strongly advocate for the use of invasive coronary physiologic assessment in all patients with intermediate coronary stenoses, real-world use shows drastic underutilization of this modality to assess for ischemia.41 As such we chose to use an angiographic QCA DS ≥70% or VE ≥80% DS as a reasonable threshold for ischemia based on its association with myocardial ischemia in ≥80% of lesions5 and a specificity for ischemia >95%.34 Similarly, we chose an angiographic QCA 60% ≥ DS or VE ≥70% DS as the threshold for ischemia in the setting of a positive exercise tolerance test based on a number of factors. Logically, it needed to be less than the QCA DS ≥70% or VE ≥80% DS angiography-alone threshold, and higher than the QCA or VE DS ≥50% threshold in the setting of a localizing stress test. Additionally, these thresholds are sensible given previous studies describing optimal VE cut-offs for ECG stress test–detected ischemia to be 70%.32 Fifth, we did not alter the algorithm for fixed perfusion defects. Fixed perfusion defects may represent scar or hibernating myocardium. Despite its potential utility, assessment of viability in practice is highly variable without consensus as to which patients, with what degree of scar, using which modality should be revascularized.42 Finally, this report represents an expert consensus from academicians, practitioners, and angiographic core laboratory directors, and was not commissioned from scientific societies.

The recently reported International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial found similar rates of composite cardiovascular death, myocardial infarction, or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest at a median follow-up of 3.2 years in patients with chronic coronary syndrome managed with guideline-directed medical therapy alone versus guideline-directed medical therapy plus routine angiography and revascularization.30 The rate and potential impact of CR by PCI and CABG in the ISCHEMIA trial have not yet been reported. The algorithms described in this report, using core laboratory assessment, have been prospectively applied to determine the frequency and impact of anatomic and ischemic CR in the ISCHEMIA trial, the results of which will be reported later in 2021.

Studies are required to determine whether a goal of CR is warranted in all situations and to assess whether ICR is more prognostically impactful after PCI than CABG, as suggested in some prior studies.43 Equally important is to assess the relative prognostic impact of anatomic versus ischemic ICR, and whether reasonable ICR offers acceptable outcomes compared with attempting to achieve CR in all patients (which may require more contrast, more radiation, and may increase procedural complications). Further analyses from ISCHEMIA evaluating CR in chronic coronary syndrome and additional studies in higher-risk patients (ie, left main and multivessel disease and left ventricular dysfunction) are also needed. In this regard, ongoing studies of the completeness of revascularization will reduce knowledge gaps and help clarify the best management revascularization strategy (or lack thereof) in patients with complex coronary artery disease.

SUMMARY AND RECOMMENDATIONS

To date, the clinical implications of ICR in most patients with coronary artery disease, especially in
those with chronic coronary syndrome, remain controversial. The reported findings to date have been confounded by the use of numerous different definitions and assessment methodologies, varying study populations, and revascularization methods. In this report, we have proposed a comprehensive yet straightforward algorithm for assessing completeness of anatomic and ischemic coronary revascularization (Figures 1 and 2) accounting for both the extent and complexity of coronary artery disease as well as physiological parameters that may be applied universally to enable greater understanding of the impact of CR versus ICR.

ARTICLE INFORMATION
Received November 9, 2020; accepted March 8, 2021.

Affiliations
Clinical Trials Center, Cardiovascular Research Foundation, New York, NY (Z.A.A., J.H., M.A.A., O.D., G.W.S.); DeMatteis Cardiovascular Institute, St. Francis Hospital, Roslyn, NY (Z.A.A., J.W.M.); New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, NY (Z.A.A., P.D., J.W.M., M.V.M.); Department of Radiology, NewYork-Presbyterian Hospital and Well Cornell Medicine, New York, NY (L.J.S.); New York University Grossman School of Medicine, New York, NY (S.B., J.S.H., H.R.); Department of Medicine, Stanford University, Stanford, CA (D.J.M.); and The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY (G.W.S.).

Sources of Funding
None.

Disclosures
Dr Ali, receives grant support, paid to his institution, and advisory board fees from Abbott Vascular; grant support and advisory board fees from Cardiovascular Systems, lecture fees from Amgen, fees for serving on a speakers’ bureau from AstraZeneca Pharmaceuticals, advisory board fees from Abiomed and Acist Medical, advisory board fees and lecture fees from Boston Scientific and Cardinal Health, advisory board fees and consulting fees from Opsens Medical, and holding equity in Shockwave Medical, Dr Bangalore, receives grant support and advisory board fees from Abbott Vascular and advisory board fees from Biotronik, Pfizer, Amgen, and Reata Pharmaceuticals, Dr Reynolds reports receives donated supplies from Abbott Vascular and BioTelemetry, Dr Stone has received speaker or other honoraria from Cook, Terumo, and Orchestra Biomed; Consultant to Valifx, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, Matrizyme, Cardiomech, Euclid Bio; Equity/options from Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, MedFocus family of funds, and Valifx. The remaining authors have no conflicts to disclose.

REFERENCES

J Am Heart Assoc. 2021;10:e020110. DOI: 10.1161/JAHA.120.020110


